TheraVet S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVET.PA research report →
About the company
TheraVet S. A. operates as a veterinary biotechnology firm, delivering specialized osteoarticular therapies for animals across Belgium, France, Switzerland, the United Kingdom, and the United States.
- CEO
- Gaetan Terrasse
- IPO
- 2021
- Employees
- 5
- HQ
- Charleroi, BE
Price Chart
- Market Cap
- $10.02M
- P/E
- -0.17
- P/S
- 9.30
- P/B
- 0.04
- EV/EBITDA
- -19.12
- Div Yield
- 0.00%
- Gross Margin
- -49.24%
- Op Margin
- -201.76%
- Net Margin
- -145.70%
- ROE
- -23.15%
- ROIC
- -29.32%
- Revenue
- $1.08M · -32.70%
- Net Income
- $-1,570,707 · 33.54%
- EPS
- $-0.49 · 32.88%
- Op Income
- $-2,175,109
- FCF YoY
- -62.14%
- 52W High
- $1.10
- 52W Low
- $0.06
- 50D MA
- $0.09
- 200D MA
- $0.22
- Beta
- -0.50
- Avg Volume
- 30.98K
Get TickerSpark's AI analysis on ALVET.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALVET.PA coverage
Recent articles, reports, and earnings notes.
No research on ALVET.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVET.PA report →Similar companies
Peers in the same neighborhood.